Maha Katabi - 05 Jun 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: JBIO
Reported as of: 05 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jun 2024, 18:00:14 UTC
Prior SEC filing: 17 May 2024
Next SEC filing: 16 May 2025
Source filing: View source filing
Reporting owner signature: /s/ George A. Eldridge, Attorney-in-Fact

Key filing fact

Maha Katabi filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 07 Jun 2024.

Key facts

This page summarizes Maha Katabi's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jun 2024, 18:00.

Change

Previous filing in this sequence was filed on 17 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 05 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $18.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.